TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The Justice Department says Michigan physician Jonathan Decker was convicted of peddling more than 2 million stimulant pills through the Done ADHD telehealth platform. Separately, the FDA cleared Click Therapeutics’ Motivista as an adjunctive treatment for negative symptoms of schizophrenia in outpatient care. The source does not provide details about the conviction, the clearance’s conditions, or the treatment’s evidence and availability.
A Michigan doctor was convicted of peddling more than 2 million stimulant pills, including Adderall, through the Done ADHD telehealth platform, the U.S. Department of Justice said. In a separate development, the FDA cleared Motivista, a prescription digital therapeutic, as an add-on treatment for negative symptoms of schizophrenia in outpatient care, according to its maker, Click Therapeutics.
The Justice Department identified the doctor as Jonathan Decker, MD, of Michigan. The report says the pills included amphetamine-dextroamphetamine salts, the generic name for Adderall, and that they were supplied through Done ADHD, a telehealth platform. The source does not specify the charges, the date or venue of the conviction, the conduct jurors considered, or any sentence imposed.
Click Therapeutics said the FDA cleared Motivista for use alongside other care to treat negative symptoms of schizophrenia in outpatient settings. Negative symptoms can include diminished motivation or social engagement, but the source provides no further detail about the product’s operation, clinical trial results, eligible patients, prescription process, or commercial availability. The clearance is a regulatory development, not a claim that the product replaces established treatment.
The two developments were included in a roundup of psychiatry news published by MedPage Today on October 7, 2026. That roundup also cited other mental health reports and policy actions, but it did not establish a connection between the doctor’s criminal case and the FDA decision.
Oversight and Digital Schizophrenia Care
The conviction puts attention on prescribing oversight in telehealth, particularly where controlled stimulants are involved. The reported volume—more than 2 million pills—signals the scale of the case, while the limited details available mean readers cannot yet assess how the prescriptions were issued, what evidence supported the verdict, or what safeguards were found lacking.
The FDA clearance is a separate development in digital mental health treatment. It gives clinicians and patients another potential adjunctive option for outpatient schizophrenia care. Its practical value will depend on details not included in the report, including the evidence behind the clearance, who can use it, how it fits with other treatment, and access and cost. Neither announcement alone establishes how widely the treatment will be used or what outcomes patients can expect.
Products Worth Considering
Fitbit Sense 2 Advanced Health and Fitness Smartwatch, Blue Mist/Pale Gold
Fitbit Sense 2 Health and Fitness Smartwatch – Shadow Grey/Graphite
Hyperice Normatec 3 Leg Compression Boots – Standard Size
As an affiliate, we earn on qualifying purchases.
Two Separate Psychiatry Developments
The source presents the conviction and Motivista clearance alongside a range of unrelated psychiatry and mental health news. It also notes that the FDA is seeking public feedback on ibogaine drug development to inform the design of future early-stage clinical trials. That request concerns a separate drug-development process and should not be confused with an approval or clearance for treatment.
The roundup further reports that anxiety about artificial intelligence is increasingly coming up in therapy sessions, citing The New York Times. This is a reported trend, not a quantified national finding in the source. The roundup also references a survey about public support for civil rights and mental illness, and a study on access to opioid-use-disorder medication among young people covered by Medicaid. Those items provide a snapshot of other current issues but do not add evidence about the doctor’s case or Motivista.
“The FDA cleared the prescription digital therapeutic Motivista as an adjunctive treatment for negative symptoms of schizophrenia in outpatient care.”
— Click Therapeutics, as summarized by MedPage Today
Case Record and Product Details Pending
The supplied report does not give the case number, specific counts of conviction, trial evidence, verdict date, or sentence for Decker. It also does not say whether an appeal is planned, whether the platform or other individuals were charged, or what changes, if any, followed the case. The reported pill total is attributed to the Justice Department; the source does not provide a separate accounting or breakdown.
For Motivista, the report does not identify the FDA clearance pathway, label restrictions, study size, measured outcomes, or any safety information. It is also unclear when the product will be available, how clinicians will prescribe or monitor it, and whether insurance will cover it. The source describes the treatment as adjunctive, but does not explain which other care it is intended to accompany.
The two developments are presented in the same roundup, with no evidence that they are related. Additional official records and company or regulator materials would be needed to answer the outstanding questions.
Watch for Sentencing and Label Details
For the criminal case, the next useful updates would be court records or a Justice Department statement detailing the conviction, any sentencing schedule, and whether Decker intends to appeal. The source does not report a sentencing date or describe a next court hearing, so no specific milestone can be confirmed.
For Motivista, clinicians and patients will need the FDA-cleared labeling and product information to understand eligibility, use, risks, and how the digital treatment is meant to fit into outpatient care. Click Therapeutics may provide further information about availability and access. Until those details are reported, the clearance confirms a regulatory step, but not how quickly patients can obtain the product or what outcomes they should expect.
Key Questions
Who was convicted in the stimulant-pill case?
The report identifies Jonathan Decker, MD, of Michigan, as the doctor convicted. It says the pills were supplied through the Done ADHD telehealth platform.
How many pills were involved?
The Justice Department, as cited by MedPage Today, said the case involved more than 2 million stimulant pills, including amphetamine-dextroamphetamine salts, commonly known as Adderall.
What did the FDA clear Motivista to treat?
Click Therapeutics said the FDA cleared Motivista as an adjunctive treatment for negative symptoms of schizophrenia in outpatient care. The source does not provide the full label or product instructions.
Does Motivista replace other schizophrenia treatment?
No such claim appears in the report. It describes Motivista as adjunctive, meaning it is intended as an add-on rather than presented there as a replacement for other care.
What key details are still unknown?
The report does not provide the doctor’s charges, sentence, or appeal status. For Motivista, it omits the clinical evidence, specific FDA labeling, availability, and coverage information.
Source: rss
